GLP1R and metabolic dysfunction-associated steatohepatitis: Out of the incretin-based drugs tested for their ability to resolve NASH, only semaglutide and liraglutide, belonging to the class of GLP-1 RAs, were found to be effective so far, but no improvement in fibrosis was observed during the clinical trials, probably due to the duration of these trials being shorter than the time needed for more pronounced changes in the liver’s fibrotic state.